HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

Balancing Cost, Utilization, and Risk in CLL Treatment: Adam Kittai, MD

Balancing Cost, Utilization, and Risk in CLL Treatment: Adam Kittai, MD

By AJMC · Jun 23, 2026 · via AJMC

This is an aggregated industry headline. Read the full story at AJMC

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineAJMC
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Julianne Hough is the new face of Revance's Botox rival Daxxify. The company has enlisted the dancer, actress …
Jun 24, 2026
Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push
The WeekFierceBiotech ↗
An under-the-radar Bay Area biotech has brought in a $190 million series B with the goal of hatching a clutch …
Jun 24, 2026
Serapha Bio launches with $230M and YolTech base-editing therapy for AATD
The WeekBriefing
Serapha Bio forms via Boundless Bio reverse merger, backed by $230M to advance SERP-01, a China-derived base-e…
Jun 24, 2026